Aleksandrova, Elena V. http://orcid.org/0000-0002-1808-5319
Wu, Kelvin J. Y. http://orcid.org/0000-0002-5561-6369
Tresco, Ben I. C.
Syroegin, Egor A. http://orcid.org/0000-0003-2753-3950
Killeavy, Erin E.
Balasanyants, Samson M. http://orcid.org/0000-0002-3987-6339
Svetlov, Maxim S. http://orcid.org/0000-0003-1459-5685
Gregory, Steven T. http://orcid.org/0000-0003-0837-9417
Atkinson, Gemma C. http://orcid.org/0000-0002-4861-4584
Myers, Andrew G. http://orcid.org/0000-0001-9602-6915
Polikanov, Yury S. http://orcid.org/0000-0002-5064-0327
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01-GM132302, R21-AI163466, R01-GM094157, R01-AI168228)
National Science Foundation (MCB-1907273)
Vetenskapsrådet (2019-01085, 2022-01603)
Knut och Alice Wallenbergs Stiftelse (2020.0037)
Carl Tryggers Stiftelse för Vetenskaplig Forskning (CTS19:24)
Article History
Received: 7 February 2023
Accepted: 11 December 2023
First Online: 18 January 2024
Competing interests
: A.G.M. is an inventor in a provisional patent application submitted by the President and Fellows of Harvard College covering oxepanoprolinamide antibiotics described in this work. A.G.M. has filed the following international patent applications: WO/2019/032936 ‘Lincosamide Antibiotics and Uses Thereof’ and WO/2019/032956 ‘Lincosamide Antibiotics and Uses Thereof’. The other authors declare no competing interests.